Pharmaceutical

2seventy bio completes $40m haemophilia A program deal with Novo Nordisk

US-based 2seventy bio has completed an asset purchase agreement (APA) to divest its haemophilia A candidate to Novo Nordisk.

Jun 28, 2024 - 04:00
2seventy bio completes $40m haemophilia A program deal with Novo Nordisk
US-based 2seventy bio has completed an asset purchase agreement (APA) to divest its haemophilia A candidate to Novo Nordisk.
Read the original article

Tags:

Previous Article

AI and stable funding environments are catalysts for biotech assets

Next Article

Verona scores FDA approval for Ohtuvayre as COPD maintenance therapy

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Pharmalittle: Medicare holds firm on Alzheimer’s drug coverage policy; Pfizer says antibiotic combo can treat some superbugs

STAT+: Pharmalittle: Medicare holds firm on Alzheimer’s...

Jun 2, 2023

Ipsen joins the ADC club with deal worth up to $900m

Ipsen joins the ADC club with deal worth up to $900m

Apr 3, 2024

FDA approves over-the-counter Narcan. Here’s what it means

FDA approves over-the-counter Narcan. Here’s what it means

Mar 30, 2023